Merz North America, Inc.

A Phase 3, Randomized, Parallel-Group, Double-Blind, Multicenter Study Investigating the Safety and Efficacy of NT 201 Compared With Placebo in Adult Participants With Moderate to Severe Platysma Prominence in the United States

Earlier

Aug 19, 2026TrialA Prospective, Multicenter, Randomized, Comparator-controlled, Evaluator-blinded Study to Evaluate the Safety and Effectiveness of Belotero® Intense Lidocaine for Lip Augmentation

Feb 10, 2023TrialLongitudinal Evaluation and Real-world Evidence of NT201

Oct 27, 2022TrialA Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

Nov 12, 2020TrialSafety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines

2 more events

Sep 23, 2020TrialSafety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Dec 21, 2018FDABendopa — INBRIJA

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

BendopaFeb 3, 2029 Bendopa4 patentsNov 16, 2032 BendopaOct 21, 2033

Regulatory

Regulatory Timeline

19823 events

FDAJan 1

Bendopa — BENDOPA

Application NDA016948 (NDA)

FDAJan 1

Bendopa — DOPAR

Application NDA016913 (NDA)

FDAJan 1

Bendopa — LARODOPA

Application NDA016912 (NDA)

20101 event

FDAJan 22

Ampyra — AMPYRA

Application NDA022250 (NDA)

20181 event

FDADec 21

Bendopa — INBRIJA

Application NDA209184 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)